Healthcare
Nuwellis Celebrates Five Years of Support of the Pediatric Cardiac Critical Care Consortium (PC⁴)
MINNEAPOLIS, June 26, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, announces the five-year anniversary of its support of the annual conference for the Pediatric Cardiac Critical Care Consortium (PC4), an alliance aiming to improve the quality of care to patients with critical pediatric and congenital cardiovascular disease. Over the past five years, Nuwellis has collaborated with l
About this update from Nuwellis, Inc.
MINNEAPOLIS, June 26, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, announces the five-year anniversary of its support of the annual conference for the Pediatric Cardiac Critical Care Consortium (PC4), an alliance aiming to improve the quality of care to patients with critical pediatric and congenital cardiovascular disease. Over the past five years, Nuwellis has collaborated with leading pediatric cardiac critical care institutions to support clinician education, scientific exchange, and awareness of fluid management strategies in critically ill children. Through these efforts, Nuwellis has helped foster dialogue around the growing clinical importance of fluid balance and the role of extracorporeal ultrafiltration therapies in pediatric intensive care settings. "Children with complex cardiac conditions face unique challenges, and effective fluid management remains an important part of care," said Nuwellis' incoming CEO Mike McCormick. "Our long-standing support of PC4 reflects our commitment to advancing education and empowering clinicians to deliver the highest level of care to children with life-threatening cardiovascular conditions and prolonged hospital stays." Many of the nation's leading pediatric cardiac centers, including several participating in PC4, utilize the Aquadex® SmartFlow® system to help manage fluid overload in complex pediatric patients. Nuwellis supports multidisciplinary care teams through ongoing education and training focused on device utilization, therapy management, and patient safety. Nuwellis' Aquadex system is designed to provide precise ultrafiltration therapy for adult and pediatric patients weighing 20 kg and above who are suffering from fluid overload. It is currently being utilized in high-acuity settings including cardiac ICUs and pediatric ICUs. Fluid overload is increasingly recognized as a significant contributor to morbidity among critically ill pediatric patients, particularly those treated in cardiac intensive care units. As pediatric clinicians seek more precise approaches to fluid management, educational initiatives supported by Nuwellis have contributed to greater awareness and discussion of evidence-based treatment strategies. "Managing fluid overload in critically ill pediatric patients remains a...